EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 290 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR “My Heart Will Always Hurt”: How I Honor My Childhood Best... April 26, 2022 FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML June 13, 2022 Working to Address Inequities in Cancer Care: 2021 ASCO Annual Meeting... July 8, 2021 Lo que deben saber las personas con cáncer de mama y... January 4, 2024 Load more HOT NEWS Dad Sings “Ave Maria” For His Daughter At Disney World FOCUS4: Learning from a landmark clinical trial For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining EU Cancer Mission and Partners Launch First Cancer Mission Forum for...
